Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XNCR vs VKTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XNCR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)

XNCR Overall Winner 6-Pillar Tally: XNCR 5 – 1 VKTX Matrix Metrics: XNCR 5 – 5 VKTX

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over Viking Therapeutics, Inc (VKTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas VKTX carries 46.5/100 (HOLD) at $26.86 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While VKTX currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. 0.0% operating margin) and revenue trajectory (+454.9% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile VKTX is in a Breakdown options structure phase (RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XNCR vs VKTX
XNCR NASDAQ Head-to-Head Winner
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap $2.9B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.21β · 87% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62
RSI-14: 62.5 · SMA20: $32.16 · SMA50: $27.52
VKTX NASDAQ
Viking Therapeutics, Inc
Pharmaceutical Preparations
$26.86
-8.08% 1D
Market Cap $3.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.52β · 74% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 45.0 Fund 53.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $26.76 · SMA50: $29.17

6-Pillar Scorecard Institutional Category Breakdown (XNCR 5 – 1 VKTX)

Columns: Metric · XNCR · VKTX
1. Valuation Multiples XNCR
Forward P/E 68.0x N/M
Trailing P/E 68.0x N/M
PEG Ratio N/M N/M
EV / Revenue 14.8x N/M
2. Growth & Scale XNCR
Revenue Growth (YoY) +454.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $200M N/A
Market Cap $2.9B $3.8B
3. Profitability & Quality VKTX
Gross Margin -42.5% N/A
Operating Margin -72.7% 0.0%
Net Profit Margin -58.8% 0.0%
Return on Equity (ROE) -19.9% -96.4%
4. Balance Sheet & Cash Flow XNCR
Cash Generation (TTM) -$176M -$463M
Cash Flow Margin -88.0% N/A
Net Cash / Leverage $101M Net Debt (0.29x D/E) $423M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XNCR
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 79.0% (10th %ile) 164.2% (88th %ile)
Put/Call OI Skew N/A 0.15x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat XNCR
OpEx & R&D Intensity 30.2% of Rev ($61M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XNCR (5) vs VKTX (5)
Institutional Metric XNCR VKTX Criterion Row Edge
Market Capitalization
Scale
$2.9B $3.8B Larger Scale VKTX
Trailing P/E Ratio
Valuation
68.0x N/M Lower Multiple XNCR
Forward P/E Ratio
Valuation
68.0x N/M Lower Multiple XNCR
Revenue Growth (YoY)
Growth
+454.9% +0.0% Higher Growth XNCR
Operating Margin (TTM)
Profitability
-72.7% 0.0% Higher Margin VKTX
Net Profit Margin
Profitability
-58.8% 0.0% Higher Margin VKTX
Return on Equity (ROE)
Capital Efficiency
-19.9% -96.4% Higher ROE XNCR
52-Week Range Position
Momentum
84% ($10–$41) 16% ($24–$43) Stronger Trend XNCR
Beta / 30D Volatility
Risk Regime
1.21β · 87% Vol 1.52β · 74% Vol Lower Realized Risk VKTX
Unified Institutional Score
Composite Signal
29.6 / 100 (SELL) 46.5 / 100 (HOLD) Higher Composite VKTX
Trailing 12M Revenue (USD)
Operating Scale
$200M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$176M ($101M Net Debt (0.29x D/E)) -$463M ($423M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +49.13 pp
XNCR: +55.84% · VKTX: +6.71%
3M Horizon XNCR +59.65 pp
XNCR: +40.14% · VKTX: -19.51%
6M Horizon XNCR +228.35 pp
XNCR: +221.97% · VKTX: -6.38%
1Y Horizon XNCR +185.67 pp
XNCR: +154.54% · VKTX: -31.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XNCR vs VKTX. Trailing 12-month operating profitability (XNCR -72.7% vs VKTX 0.0%) and valuation multiples (XNCR 68.0x vs VKTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XNCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$200M
Gross Margin-42.5%
Op. Margin-72.7%
ROE / Fwd P/E-19.9% · 68.0x
VKTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-96.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XNCR BREAKOUT
58d in phase · OBV ACCUMULATION
Current IV 79.0%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VKTX BREAKDOWN
93d in phase · OBV NEUTRAL
Current IV 164.2%
IV Percentile 88th %ile
Put/Call OI Skew 0.15x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VKTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published
VKTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XNCR vs VKTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over Viking Therapeutics, Inc (VKTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas VKTX carries 46.5/100 (HOLD) at $26.86 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VKTX currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. 0.0% operating margin) and revenue trajectory (+454.9% vs. +0.0% YoY). Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile VKTX is in a Breakdown options structure phase (RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XNCR leads the Growth & Scale pillar: XNCR posts +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin), compared with VKTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, XNCR generates $200M in USD-normalized revenue versus N/A for VKTX. In operating R&D and SG&A reinvestment, XNCR deploys 30.2% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VKTX.

XNCR screens cheaper on headline valuation multiples. XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin), whereas VKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XNCR (-19.9% ROE) versus VKTX (-96.4% ROE) capital efficiency.

In options market volatility and institutional positioning, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk). By comparison, VKTX carries 164.2% implied volatility (88th %ile, Extreme (>80th %ile)), a 0.15x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.